ECSP16086247A - (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina - Google Patents

(s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina

Info

Publication number
ECSP16086247A
ECSP16086247A ECIEPI201686247A ECPI201686247A ECSP16086247A EC SP16086247 A ECSP16086247 A EC SP16086247A EC IEPI201686247 A ECIEPI201686247 A EC IEPI201686247A EC PI201686247 A ECPI201686247 A EC PI201686247A EC SP16086247 A ECSP16086247 A EC SP16086247A
Authority
EC
Ecuador
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
medicine
pain
Prior art date
Application number
ECIEPI201686247A
Other languages
English (en)
Inventor
Filipe Augusto Eugenio Pardal
Caixado Carlos Alberto Eufrasio Casimiro
Pecorelli Susana Marques Almeida
Joao Carlos Ramos Damil
Ana Sofia Da Conceicao Lopes
Pedroso Pedro Filipe Eufrasio
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of ECSP16086247A publication Critical patent/ECSP16086247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)

Abstract

(S)-pirlindole o sus sales farmacéuticamente aceptables, así como composiciones farmacéuticas que comprenden el mismo para uso en el tratamiento terapéutico y prevención del dolor.
ECIEPI201686247A 2014-05-09 2016-11-09 (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina ECSP16086247A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000029 WO2015171005A1 (en) 2014-05-09 2014-05-09 (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine

Publications (1)

Publication Number Publication Date
ECSP16086247A true ECSP16086247A (es) 2017-02-24

Family

ID=50819931

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201686247A ECSP16086247A (es) 2014-05-09 2016-11-09 (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina

Country Status (30)

Country Link
US (1) US9814712B2 (es)
EP (1) EP3057589B1 (es)
JP (1) JP6768520B2 (es)
KR (1) KR102298676B1 (es)
CN (1) CN106456637B (es)
AU (1) AU2014393490B2 (es)
CA (1) CA2948598C (es)
CY (1) CY1119532T1 (es)
DK (1) DK3057589T3 (es)
EC (1) ECSP16086247A (es)
ES (1) ES2649492T3 (es)
HR (1) HRP20171651T1 (es)
HU (1) HUE035071T2 (es)
IL (1) IL248855B (es)
LT (1) LT3057589T (es)
MA (1) MA39447B1 (es)
MX (1) MX368734B (es)
NO (1) NO3057589T3 (es)
NZ (1) NZ726132A (es)
PH (1) PH12016502233A1 (es)
PL (1) PL3057589T3 (es)
PT (1) PT3057589T (es)
RS (1) RS56591B1 (es)
RU (1) RU2695647C2 (es)
SA (1) SA516380264B1 (es)
SI (1) SI3057589T1 (es)
SM (1) SMT201700519T1 (es)
TN (1) TN2016000498A1 (es)
UA (1) UA118474C2 (es)
WO (1) WO2015171005A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400359T1 (it) * 2014-05-09 2024-11-15 Tecnimede Sociedade Tecnico Medicinal S Sali mandelati degli enantiomeri del pirlindolo per l'uso in medicina
TN2016000497A1 (en) 2014-05-09 2018-04-04 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EP3392251A1 (en) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of pirlindole enantiomers and its salts
EP3392250A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of piperazine ring for the synthesis of pyrazinocarbazole derivatives
MX2018011142A (es) 2018-09-13 2019-10-10 Federico Amezcua Amezcua Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
EP3900716A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Co-crystal of gabapentin, ketoprofen and lysine, pharmaceutical compositions and their medical use
CN117717546A (zh) * 2023-10-20 2024-03-19 四川大学华西医院 一种吲哚类衍生物在制备预防和/或治疗疼痛的药物中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
AU2003292936A1 (en) * 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2007505831A (ja) * 2003-09-15 2007-03-15 ベクトゥラ・リミテッド 肺吸入による、早漏を治療するための医薬品組成物
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
SMT202400359T1 (it) * 2014-05-09 2024-11-15 Tecnimede Sociedade Tecnico Medicinal S Sali mandelati degli enantiomeri del pirlindolo per l'uso in medicina

Also Published As

Publication number Publication date
CN106456637A (zh) 2017-02-22
SMT201700519T1 (it) 2018-01-11
EP3057589A1 (en) 2016-08-24
JP6768520B2 (ja) 2020-10-14
WO2015171005A1 (en) 2015-11-12
CN106456637B (zh) 2020-06-09
KR102298676B1 (ko) 2021-09-07
CA2948598A1 (en) 2015-11-12
MX2016014699A (es) 2017-05-02
UA118474C2 (uk) 2019-01-25
NO3057589T3 (es) 2017-12-30
HUE035071T2 (en) 2018-05-02
PH12016502233A1 (en) 2017-02-06
SI3057589T1 (sl) 2017-12-29
EP3057589B1 (en) 2017-08-02
RU2016148183A (ru) 2018-06-13
HRP20171651T1 (hr) 2017-12-15
RU2016148183A3 (es) 2018-06-13
RS56591B1 (sr) 2018-02-28
US9814712B2 (en) 2017-11-14
MX368734B (es) 2019-10-14
PL3057589T3 (pl) 2018-01-31
CY1119532T1 (el) 2018-03-07
NZ726132A (en) 2019-02-22
TN2016000498A1 (en) 2018-04-04
US20170143709A1 (en) 2017-05-25
LT3057589T (lt) 2017-11-27
RU2695647C2 (ru) 2019-07-25
IL248855A0 (en) 2017-01-31
KR20170002434A (ko) 2017-01-06
JP2017518979A (ja) 2017-07-13
CA2948598C (en) 2021-06-08
MA39447A1 (fr) 2017-10-31
SA516380264B1 (ar) 2019-07-29
AU2014393490B2 (en) 2020-01-02
PT3057589T (pt) 2017-11-29
DK3057589T3 (da) 2017-11-13
ES2649492T3 (es) 2018-01-12
IL248855B (en) 2020-05-31
MA39447B1 (fr) 2018-05-31
AU2014393490A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
MX378273B (es) Compuestos activos hacia bromodominios.
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
ES3057783T3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX384447B (es) Composiciones farmacéuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor